The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings
Open Access
- 3 May 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 20 (4) , 403-413
Abstract
Human genetic research has succeeded in definitively identifying multiple genetic variants associated with risk for nicotine dependence and heavy smoking. To build on these advances, and to aid in reducing the prevalence of smoking and its consequent health harms, the next frontier is to identify genetic predictors of successful smoking cessation and also of the efficacy of smoking cessation treatments (“pharmacogenomics”). More broadly, additional biomarkers that can be quantified from biosamples also promise to aid “Precision Medicine” and the personalization of treatment, both pharmacological and behavioral. To motivate ongoing and future efforts, here we review several compelling genetic and biomarker findings related to smoking cessation and treatment. These Key results involve genetic variants in the nicotinic receptor subunit gene CHRNA5, variants in the nicotine metabolism gene CYP2A6, and the nicotine metabolite ratio. We also summarize reports of epigenetic changes related to smoking behavior. The results to date demonstrate the value and utility of data generated from biosamples in clinical treatment trial settings. This article cross-references a companion paper in this issue that provides practical guidance on how to incorporate biosample collection into a planned clinical trial and discusses avenues for harmonizing data and fostering consortium-based, collaborative research on the pharmacogenomics of smoking cessation. Evidence is emerging that certain genotypes and biomarkers are associated with smoking cessation success and efficacy of smoking cessation treatments. We review key findings that open potential avenues for personalizing smoking cessation treatment according to an individual’s genetic or metabolic profile. These results provide important incentive for smoking cessation researchers to collect biosamples and perform genotyping in research studies and clinical trials.Keywords
Funding Information
- National Institute on Drug Abuse (R01 DA026911, DA030398, R01 DA038076, HHSN271201300004C, R43 DA041211, R21DA033813, R01 DA017441, U54 MD010724, R01DA036583, DA020830)
- University of Bristol (MC_UU_12013/2)
- Oak Foundation
- Canadian Institutes of Health Research (DC0190SR)
- Canadian Cancer Society (703187, 703404)
This publication has 117 references indexed in Scilit:
- Tobacco Smoking Leads to Extensive Genome-Wide Changes in DNA MethylationPLOS ONE, 2013
- Smoking and Genetic Risk Variation Across Populations of European, Asian, and African American Ancestry—A Meta‐Analysis of Chromosome 15q25Genetic Epidemiology, 2012
- The interplay of genes and adolescent development in substance use disorders: leveraging findings from GWAS meta-analyses to test developmental hypotheses about nicotine consumptionHuman Genetics, 2012
- High density DNA methylation array with single CpG site resolutionGenomics, 2011
- Rare Nonsynonymous Variants in Alpha-4 Nicotinic Acetylcholine Receptor Gene Protect Against Nicotine DependenceBiological Psychiatry, 2011
- Tobacco-Smoking-Related Differential DNA Methylation: 27K Discovery and ReplicationThe American Journal of Human Genetics, 2011
- Genetic Vulnerability and Susceptibility to Substance DependenceNeuron, 2011
- A Randomized Placebo-Controlled Clinical Trial of 5 Smoking Cessation PharmacotherapiesArchives of General Psychiatry, 2009
- Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation studyPharmacology Biochemistry and Behavior, 2009
- Nicotine Chemistry, Metabolism, Kinetics and Biomarkers2009